GlassScriptPhysician profile
Andrew D Atiemo
NPI 1285678748
$3,033.37
in general payments reported to CMS, 2019-2025
25 companies · $315 in 2025
The $315 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $382 · 2020: $187 · 2021: $393 · 2022: $383 · 2023: $623 · 2024: $751 · 2025: $315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,689.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,688.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $701.34 | 2020-2025 | Resonate El Icd Vr, Emblem Mri S-Icd, Fineline II Sterox |
| Edwards Lifesciences Corporation | $456.72 | 2021-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Abiomed | $263.67 | 2019-2024 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $246.45 | 2019-2024 | Lifevest |
| Amgen INC. | $215.97 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $167.76 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $160.22 | 2019-2023 | Xarelto |
| Chiesi USA, INC. | $137.07 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $122.64 | 2019-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $87.69 | 2019-2024 | |
| Cardiva Medical, INC. | $66.99 | 2025 | Ensoetm, Cardiva Vascade Mvp Vvcs 6-12f |
| Abbott Laboratories | $62.68 | 2020-2022 | |
| Actelion Pharmaceuticals US, INC. | $52.01 | 2022-2024 | Uptravi, Opsumit |
| Kiniksa Pharmaceuticals International, Plc | $42.12 | 2024 | Arcalyst |
| Astrazeneca Pharmaceuticals LP | $38.46 | 2019-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, LTD. | $35.46 | 2023 | Arcalyst |
| Bardy Diagnostics, INC. | $30.00 | 2020 | |
| Philips North America LLC | $24.75 | 2023 | |
| Xeris Pharmaceuticals, INC. | $23.80 | 2024 | Keveyis |
| Esperion Therapeutics, INC. | $19.71 | 2022 | |
| Amarin Pharma, INC. | $17.77 | 2021 | |
| Merck Sharp & Dohme LLC | $16.00 | 2022 | |
| Teleflex LLC | $15.56 | 2023 | Vascband |
| Lexicon Pharmaceuticals, INC. | $15.42 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $13.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Atiemo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.